Story thread · 4 reports / 3 sources

STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years

statnews.com · 2h · first report

STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years

How the coverage leans

Across 3 sources · syndicated copies counted once

UniQure's gene therapy continues to slow Huntington's progression after four years. But the magnitude of the benefit waned compared to a similar analysis from a year ago.

The coverage

  1. uniQure plunges 65% as 48-month Huntington’s gene therapy data misses key stat

    investing.com · 1h

  2. UniQure’s Huntington’s Drug Shows Weaker Benefit After Four Years in Trial

    bloomberg.com · 2h

The conversation · 0

Sign in to join the conversation.

No comments yet — start the thread.